<DOC>
	<DOCNO>NCT01281098</DOCNO>
	<brief_summary>To evaluate safety determine efficacy PRP monotherapy combination therapy ( pegaptanib 0.3 mg plus PRP ) patient Type I Type II diabetes mellitus high risk proliferative diabetic retinopathy .</brief_summary>
	<brief_title>Prospective , Randomized , Open Label , Phase II Study Assess Efficacy Safety Macugen® ( Pegaptanib 0.3 mg Intravitreal Injections ) Plus Panretinal Photocoagulation PRP ( Monotherapy ) Treatment With High Risk PDR .</brief_title>
	<detailed_description>Panretinal photocoagulation ( PRP ) cause regression retinal neovascularization reduce risk severe vision loss people proliferative diabetic retinopathy ( PDR ) . However , destructive treatment may associate side effect ( e.g . pain , transient blurring , loss peripheral and/or night vision , increase risk macular edema central vision loss ) always efficient regression neovascularization . Vascular endothelial growth factor ( VEGF ) show play role retinal neovascularization retinal vascular leakage relate PDR diabetic macular edema . Anti-VEGF treatment hypothesize adjunctive treatment management retinal neovascularization macular edema relate diabetic retinopathy ( DR ) . Anti-VEGF agent , Macugen® , combine PRP expect control neovascularization without need photocoagulation posterior pole , around macula , thus avoid major side effect standard PRP ( visual field loss ) . A modification panretinal photocoagulation ( PRP ) recently propose Madeira et al. , ( 2009 ) 2009 EURETINA Meeting . The described technique involve progressive application DRS photocoagulation ring different sequence . First ring : corresponds DRS third ring , extrude os serrata midperiphery . Second ring : corresponds DRS second ring , extrude midperiphery towards vortex vein . Third ring : corresponds DRS first ring , perform necessary . This technique result less aggressive visual field loss achieve result peripheral photocoagulation . The combination intravitreal anti-VEGF treatment pegaptanib , series 3 injection injected reverse neovascularization , maintain macula dry complete long term effect panretinal photocoagulation . This peripheral photocoagulation propose expect eliminate chronic VEGF stimulus eliminate chronic ischemic factor , maintain visual field useful daily activity drive , etc .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Highrisk proliferative diabetic retinopathy ( HRPDR ) eye ( defined section 2 ) . BCVA baseline &gt; 20/320 ( 25 letter ETDRS Chart ) study eye . Clear ocular medium adequate pupillary dilatation permit good quality fundus photography . Intraocular pressure &lt; 21 mmHg . Type I , Type II diabetic subject define WHO criteria either gender , age ≥ 18 year . Women must use effective contraception , postmenopausal least 12 month prior trial entry , surgically sterile . Ability provide write informed consent . Ability return trial visit . Eyes prior scatter ( panretinal ) . Focal/grid photocoagulation , within previous 6 month . Fibrovascular proliferation retinal traction . Other cause retinal neovascularization ( retinal vein occlusion , radiation retinopathy others ) . Atrophy/scarring/fibrosis/ hard exudate involve center macula . Subjects receive YAG laser within previous 6 month . Peripheral retinal cryoablation , laser retinopexy ( retinal tear ) , Significant medium opacity , might interfere visual acuity , assessment toxicity fundus photography . Subjects enter likelihood require cataract surgery within follow 1 year . Any intraocular surgery within 6 month trial enrolment . Previous vitrectomy . HbA1C level &gt; 11 % recent sign uncontrolled diabetes . Any following underlying systemic disease : History evidence severe cardiac disease , e.g . NYHA Functional Class III IV , clinical medical history unstable angina , acute coronary syndrome , myocardial infarction , revascularization procedure within 6 month prior baseline , ventricular tachyarrhythmia require treatment . History evidence clinically significant peripheral vascular disease intermittent claudication prior amputation . Clinically significant impair renal function ( serum creatinine &gt; 2.5 mg/dL s/p renal transplant receive dialysis ) . Clinically significant impair hepatic function . Stroke ( within 12 month trial entry ) . Any major surgical procedure within one month trial enrolment . Previous radiation head region study eye . Any prior treatment investigational agent diabetic retinopathy antiVEGF therapy ( include intravitreal , subconjunctival subtenons corticosteroid ) past 90 day condition . Known serious allergy fluorescein use angiography , component Macugen® formulation . Systolic BP &gt; 170 ( 2 different reading ) diastolic BP &gt; 100 ( 2 different reading ) . Acute ocular periocular infection . Previous filter surgery ( e.g. , trabeculectomy ) placement glaucoma drainage devise ( e.g. , tubeshunt surgery ) . Use investigational drug time enrollment . History hypersensitivity study drug drug similar chemical class . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) . Women childbearing potential , defined woman physiologically capable become pregnant UNLESS : woman whose career , lifestyle , sexual orientation precludes intercourse male partner ; woman whose partner sterilize vasectomy mean use highly effective method birth control ( i.e . one result less 1 % per year failure rate use consistently correctly , implant , injectables , combine oral contraceptive , intrauterine device IUDs ) . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) acceptable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>High Risk Proliferative Diabetic Retinopathy</keyword>
	<keyword>Diabetes Mellitus Type I , Type II</keyword>
	<keyword>Pegaptanib</keyword>
	<keyword>Panretinal Photocoagulation</keyword>
</DOC>